NASDAQ:CBMG - Cellular Biomedicine Group Stock Price, Forecast & News

Cellular Biomedicine Group trades on the NASDAQ under the ticker symbol "CBMG."

Cellular Biomedicine Group Inc (NASDAQ:CBMG) issued its earnings results on Tuesday, February, 19th. The biotechnology company reported ($0.45) EPS for the quarter, missing the Zacks' consensus estimate of ($0.44) by $0.01. The biotechnology company had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.05 million. View Cellular Biomedicine Group's Earnings History.

Cellular Biomedicine Group is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Cellular Biomedicine Group.

3 brokerages have issued 12 month price objectives for Cellular Biomedicine Group's stock. Their forecasts range from $19.00 to $27.00. On average, they expect Cellular Biomedicine Group's stock price to reach $21.67 in the next year. This suggests a possible upside of 27.2% from the stock's current price. View Analyst Price Targets for Cellular Biomedicine Group.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellular Biomedicine Group in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellular Biomedicine Group.

Media coverage about CBMG stock has been trending somewhat positive this week, according to InfoTrie. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cellular Biomedicine Group earned a news impact score of 1.8 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Cellular Biomedicine Group.

Cellular Biomedicine Group saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 560,400 shares, an increase of 18.8% from the December 31st total of 471,600 shares. Based on an average daily volume of 53,300 shares, the short-interest ratio is currently 10.5 days. Currently, 4.1% of the shares of the company are short sold. View Cellular Biomedicine Group's Current Options Chain.

Some companies that are related to Cellular Biomedicine Group include I-Mab (BDTX), Orchard Therapeutics (ORTX), NanoString Technologies (NSTG), Krystal Biotech (KRYS), Twist Bioscience (TWST), Adverum Biotechnologies (ADVM), BAVARIAN NORDIC/S (BVNRY), Mesoblast (MESO), Aerie Pharmaceuticals (AERI), AVITA MED LTD/S (RCEL), Sangamo Therapeutics (SGMO), DBV TECHNOLOGIE/S (DBVT), Vericel (VCEL), Proteon Therapeutics (PRTO) and Atara Biotherapeutics (ATRA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellular Biomedicine Group investors own include Crispr Therapeutics (CRSP), Aduro BioTech (ADRO), Anavex Life Sciences (AVXL), Exelixis (EXEL), Fate Therapeutics (FATE), Viewray (VRAY), Adaptimmune Therapeutics (ADAP), Agile Therapeutics (AGRX), Amarin (AMRN) and Inovio Pharmaceuticals (INO).

Cellular Biomedicine Group's stock is owned by a number of of retail and institutional investors. Top institutional investors include Platinum Investment Management Ltd. (3.71%), Nikko Asset Management Americas Inc. (2.76%), Sumitomo Mitsui Trust Holdings Inc. (2.76%), ARK Investment Management LLC (2.14%), State Street Corp (1.19%) and Russell Investments Group Ltd. (0.35%). View Institutional Ownership Trends for Cellular Biomedicine Group.

CBMG stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc. and Nikko Asset Management Americas Inc.. View Insider Buying and Selling for Cellular Biomedicine Group.

CBMG stock was purchased by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Russell Investments Group Ltd., Platinum Investment Management Ltd., State Street Corp, Vident Investment Advisory LLC, UBS Group AG, California Public Employees Retirement System and Meeder Asset Management Inc.. View Insider Buying and Selling for Cellular Biomedicine Group.

Shares of CBMG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CBMG stock can currently be purchased for approximately $17.04.

Cellular Biomedicine Group has a market capitalization of $328.53 million and generates $220,000.00 in revenue each year. The biotechnology company earns $-38,930,000.00 in net income (profit) each year or ($2.04) on an earnings per share basis. Cellular Biomedicine Group employs 193 workers across the globe.View Additional Information About Cellular Biomedicine Group.

The official website for Cellular Biomedicine Group is http://www.cellbiomedgroup.com/.

Cellular Biomedicine Group's mailing address is 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA, 95014. The biotechnology company can be reached via phone at 408-973-7884 or via email at [email protected]